Phaseline

Companies › Kahr Medical

Kahr Medical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DSP107
SIRPα-4-1BBL bi-functional fusion protein; engages SIRPα on macrophages (CD172a) to block
SIRPA, TNFPhase 1Advanced Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04440735DSP107Phase 1Advanced Solid TumorOncologySep 2025

Targets

SIRPA (1) TNF (1)

Companies with the same targets

FBD Biologics Sairopa Electra Therapeutics Byondis Chia Tai Tianqing Pharmaceutical Group Prestige Biopharma Philogen Taizhou Mabtech Pharmaceutical Chiesi Farmaceutici Johnson & Johnson (Janssen)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.